Share-based Payment Arrangement, Expense of Aptose Biosciences Inc. from 30 Jun 2017 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Aptose Biosciences Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2017 to 30 Sep 2025.
  • Aptose Biosciences Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $44,000.
  • Aptose Biosciences Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $491,000, a 65% decline year-over-year.
  • Aptose Biosciences Inc. annual Share-based Payment Arrangement, Expense for 2024 was $1,060,000, a 71% decline from 2023.
  • Aptose Biosciences Inc. annual Share-based Payment Arrangement, Expense for 2023 was $3,653,000, a 30% decline from 2022.
  • Aptose Biosciences Inc. annual Share-based Payment Arrangement, Expense for 2022 was $5,207,000, a 60% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Aptose Biosciences Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $491,000 $44,000 +$57,000 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $434,000 $64,000 -$143,000 -69% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $577,000 $326,000 -$483,000 -60% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $1,060,000 $57,000 -$354,000 -86% 01 Oct 2024 31 Dec 2024 10-K 28 Mar 2025 2024 FY
Q3 2024 $1,414,000 $13,000 -$612,000 -102% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $2,026,000 $207,000 -$562,000 -73% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $2,588,000 $809,000 -$1,065,000 -57% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $3,653,000 $411,000 -$450,000 -52% 01 Oct 2023 31 Dec 2023 10-K 28 Mar 2025 2024 FY
Q3 2023 $4,103,000 $599,000 -$454,000 -43% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $4,557,000 $769,000 -$10,000 -1.3% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $4,567,000 $1,874,000 -$640,000 -25% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $5,207,000 $861,000 -$1,453,000 -63% 01 Oct 2022 31 Dec 2022 10-K 26 Mar 2024 2023 FY
Q3 2022 $6,660,000 $1,053,000 -$775,000 -42% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $7,435,000 $779,000 -$1,385,000 -64% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $8,820,000 $2,514,000 -$4,129,000 -62% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q4 2021 $12,949,000 $2,314,000 -$2,117,000 -48% 01 Oct 2021 31 Dec 2021 10-K 24 Mar 2023 2022 FY
Q3 2021 $15,066,000 $1,828,000 -$3,077,000 -63% 01 Jul 2021 30 Sep 2021 10-Q 01 Nov 2022 2022 Q3
Q2 2021 $18,143,000 $2,164,000 -$5,537,000 -72% 01 Apr 2021 30 Jun 2021 10-Q 02 Aug 2022 2022 Q2
Q1 2021 $23,680,000 $6,643,000 +$2,242,000 +51% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 $21,438,000 $4,431,000 +$3,869,000 +688% 01 Oct 2020 31 Dec 2020 10-K 22 Mar 2022 2021 FY
Q3 2020 $17,569,000 $4,905,000 +$4,401,000 +873% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $13,168,000 $7,701,000 +$7,133,000 +1256% 01 Apr 2020 30 Jun 2020 10-Q 03 Aug 2021 2021 Q2
Q1 2020 $6,035,000 $4,401,000 +$3,739,000 +565% 01 Jan 2020 31 Mar 2020 10-Q 04 May 2021 2021 Q1
Q4 2019 $2,296,000 $562,000 -$20,000 -3.4% 01 Oct 2019 31 Dec 2019 10-K 23 Mar 2021 2020 FY
Q3 2019 $2,316,000 $504,000 -$447,000 -47% 01 Jul 2019 30 Sep 2019 10-Q 10 Nov 2020 2020 Q3
Q2 2019 $2,763,000 $568,000 +$53,000 +10% 01 Apr 2019 30 Jun 2019 10-Q 04 Aug 2020 2020 Q2
Q1 2019 $2,710,000 $662,000 -$1,566,000 -70% 01 Jan 2019 31 Mar 2019 10-Q 05 May 2020 2020 Q1
Q4 2018 $4,276,000 $582,000 01 Oct 2018 31 Dec 2018 10-K 10 Mar 2020 2019 FY
Q3 2018 $951,000 +$796,000 +514% 01 Jul 2018 30 Sep 2018 10-Q 05 Nov 2019 2019 Q3
Q2 2018 $515,000 +$66,000 +15% 01 Apr 2018 30 Jun 2018 10-Q 06 Aug 2019 2019 Q2
Q1 2018 $2,228,000 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019 2019 Q1
Q3 2017 $155,000 01 Jul 2017 30 Sep 2017 8-K 12 Mar 2019 2018 Q3
Q2 2017 $449,000 01 Apr 2017 30 Jun 2017 8-K 12 Mar 2019 2018 Q2

Aptose Biosciences Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $1,060,000 -$2,593,000 -71% 01 Jan 2024 31 Dec 2024 10-K 28 Mar 2025 2024 FY
2023 $3,653,000 -$1,554,000 -30% 01 Jan 2023 31 Dec 2023 10-K 28 Mar 2025 2024 FY
2022 $5,207,000 -$7,742,000 -60% 01 Jan 2022 31 Dec 2022 10-K 26 Mar 2024 2023 FY
2021 $12,949,000 -$8,489,000 -40% 01 Jan 2021 31 Dec 2021 10-K 24 Mar 2023 2022 FY
2020 $21,438,000 +$19,142,000 +834% 01 Jan 2020 31 Dec 2020 10-K 22 Mar 2022 2021 FY
2019 $2,296,000 -$1,980,000 -46% 01 Jan 2019 31 Dec 2019 10-K 23 Mar 2021 2020 FY
2018 $4,276,000 +$4,215,000 +6910% 01 Jan 2018 31 Dec 2018 10-K 10 Mar 2020 2019 FY
2017 $61,000 01 Jan 2017 31 Dec 2017 8-K 12 Mar 2019 2018 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.